PE20171258A1 - Inhalador de polvo seco que comprende propionato de fluticasona y xinafoato de salmeterol - Google Patents

Inhalador de polvo seco que comprende propionato de fluticasona y xinafoato de salmeterol

Info

Publication number
PE20171258A1
PE20171258A1 PE2017001234A PE2017001234A PE20171258A1 PE 20171258 A1 PE20171258 A1 PE 20171258A1 PE 2017001234 A PE2017001234 A PE 2017001234A PE 2017001234 A PE2017001234 A PE 2017001234A PE 20171258 A1 PE20171258 A1 PE 20171258A1
Authority
PE
Peru
Prior art keywords
dry powder
fluticasone propionate
powder inhaler
salmeterol xinafoate
inhaler including
Prior art date
Application number
PE2017001234A
Other languages
English (en)
Inventor
Mukul Dalvi
Seah Kee Tee
Original Assignee
Teva Branded Pharmaceutical Products Randd Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55443303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20171258(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Branded Pharmaceutical Products Randd Inc filed Critical Teva Branded Pharmaceutical Products Randd Inc
Publication of PE20171258A1 publication Critical patent/PE20171258A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
    • A61M15/0006—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means
    • A61M15/0008—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means rotating by airflow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se refiere a un inhalador de polvo seco que comprende: un medicamento en polvo seco caracterizado porque comprende propionato de fluticasona, xinafoato de salmeterol y un portador de lactosa; en donde, la dosis administrada de propionato de fluticasona por accionamiento es inferior a 100 microgramos; y en donde la dosis proporciona un FEV1 ajustado al inicio en un paciente de mas de 150 mL dentro de los 30 minutos despues de recibir la dosis. Tambien se refiere a un metodo de tratamiento
PE2017001234A 2015-01-20 2016-01-20 Inhalador de polvo seco que comprende propionato de fluticasona y xinafoato de salmeterol PE20171258A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562105479P 2015-01-20 2015-01-20

Publications (1)

Publication Number Publication Date
PE20171258A1 true PE20171258A1 (es) 2017-08-28

Family

ID=55443303

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017001234A PE20171258A1 (es) 2015-01-20 2016-01-20 Inhalador de polvo seco que comprende propionato de fluticasona y xinafoato de salmeterol

Country Status (19)

Country Link
US (2) US9415008B2 (es)
EP (1) EP3247331A1 (es)
JP (1) JP2018503687A (es)
KR (1) KR20170103975A (es)
CN (1) CN107530357A (es)
AR (1) AR104771A1 (es)
AU (2) AU2016209363B2 (es)
BR (1) BR112017015353A2 (es)
CA (1) CA2974125A1 (es)
CL (1) CL2017001859A1 (es)
CO (1) CO2017008395A2 (es)
EA (1) EA201791632A1 (es)
HK (1) HK1245125A1 (es)
IL (1) IL253499A0 (es)
MA (1) MA41378A (es)
MX (2) MX383344B (es)
PE (1) PE20171258A1 (es)
TW (1) TW201628607A (es)
WO (1) WO2016118589A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX374870B (es) * 2013-10-07 2025-03-06 Teva Branded Pharmaceutical Products R&D Inc Inhalador de polvo seco.
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
US11344685B2 (en) 2016-11-18 2022-05-31 Norton (Waterford) Limited Drug delivery device with electronics
CN110201278B (zh) * 2018-02-28 2021-07-30 张江 用于吸入给药的药盒和吸入给药组合结构
CN110201280B (zh) * 2018-02-28 2021-07-30 张江 用于吸入给药装置的吸嘴和吸入给药装置
CN110201281B (zh) * 2018-02-28 2021-08-06 张江 吸入给药装置和吸入给药组合结构
CN110064110A (zh) * 2019-05-29 2019-07-30 上海理工大学 一种容积旋钮式干粉储存吸入装置
GB2585206B (en) 2019-07-01 2021-08-11 Merxin Ltd Portable inhaler

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
TWI224511B (en) 2000-06-23 2004-12-01 Norton Healthcare Ltd De-agglomerator for breath-actuated dry powder inhaler
TWI224512B (en) * 2000-06-23 2004-12-01 Norton Healthcare Ltd Reservoir pressure system for medicament inhaler
AR030516A1 (es) * 2000-08-31 2003-08-20 Glaxo Group Ltd Uso de una combinacion de salmeterol y fluticasona
ES2474199T3 (es) * 2000-11-30 2014-07-08 Vectura Limited Composiciones farmacéuticas para inhalaci�n
GB0124523D0 (en) * 2001-10-12 2001-12-05 Glaxo Group Ltd Pharmaceutical combination
US20040105821A1 (en) 2002-09-30 2004-06-03 Howard Bernstein Sustained release pharmaceutical formulation for inhalation
US9114081B2 (en) * 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
PL3111927T3 (pl) * 2009-05-29 2020-06-29 Pearl Therapeutics, Inc. Kompozycje do wziewnego podawania środków aktywnych oraz związane z nimi sposoby i systemy
WO2011035128A1 (en) * 2009-09-17 2011-03-24 Mutual Pharmaceutical Company, Inc. Method of treating asthma with antiviral agents
GB0919465D0 (en) 2009-11-06 2009-12-23 Norton Healthcare Ltd Airflow adaptor for a breath-actuated dry powder inhaler
MX339742B (es) * 2010-05-18 2016-06-07 Teva Pharma Ireland Contadores de dosis para inhaladores, inhaladores y flechas de los mismos.
EP2571486A4 (en) 2010-05-20 2013-12-04 Sun Pharma Advanced Res Co Ltd DRY POWDER INHALATION COMPOSITION
KR20130140358A (ko) * 2012-06-14 2013-12-24 한미약품 주식회사 살메테롤 지나포산염, 플루티카손 프로피오네이트 및 티오트로피움 브로마이드를 포함하는 흡입 제형용 건조 분말 및 이의 제조방법
MX2015015150A (es) * 2013-04-29 2016-02-18 Sanofi Sa Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
CA2910976C (en) * 2013-05-03 2021-03-30 Dow Global Technologies Llc Process for equilibrium-limited reactions
MX374870B (es) 2013-10-07 2025-03-06 Teva Branded Pharmaceutical Products R&D Inc Inhalador de polvo seco.
BR112017007587A2 (pt) * 2014-10-16 2018-01-30 Teva Branded Pharmaceutical Products R&D Inc processo para preparar uma formulação farmacêutica em pó seca e inalável
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol

Also Published As

Publication number Publication date
CO2017008395A2 (es) 2018-01-05
TW201628607A (zh) 2016-08-16
CA2974125A1 (en) 2016-07-28
IL253499A0 (en) 2017-09-28
US20160206559A1 (en) 2016-07-21
AR104771A1 (es) 2017-08-16
WO2016118589A1 (en) 2016-07-28
US20180015035A1 (en) 2018-01-18
MX2021006751A (es) 2021-07-15
US9415008B2 (en) 2016-08-16
AU2021202784A1 (en) 2021-05-27
JP2018503687A (ja) 2018-02-08
AU2016209363B2 (en) 2021-02-04
MX2017009122A (es) 2017-10-12
AU2016209363A1 (en) 2017-08-24
CL2017001859A1 (es) 2018-04-06
CN107530357A (zh) 2018-01-02
HK1245125A1 (zh) 2018-08-24
EP3247331A1 (en) 2017-11-29
KR20170103975A (ko) 2017-09-13
EA201791632A1 (ru) 2017-12-29
MA41378A (fr) 2017-11-28
MX383344B (es) 2025-03-13
BR112017015353A2 (en) 2018-01-16

Similar Documents

Publication Publication Date Title
MX2016004316A (es) Inhalador de polvo seco.
PE20171258A1 (es) Inhalador de polvo seco que comprende propionato de fluticasona y xinafoato de salmeterol
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX2015013355A (es) Terapia que involucra anticuerpos contra claudina 18.2 para el tratamiento de cancer.
CO2022004902A2 (es) Anticuerpo anti beta-amiloide para el tratamiento de la enfermedad de alzheimer
MX2016005666A (es) Anticuerpos anti-cd38 especificos para tratar canceres humanos.
BR112015029918A2 (pt) uso de alta dose de pridopidina para tratar a doença de huntington
IN2015DN00376A (es)
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
AR095338A1 (es) Método de tratamiento no tóxico para la abstinencia de drogas
HK1245153A1 (zh) Btk抑制剂组合和给药方案
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
AR100369A1 (es) Composición de dosis fija de formoterol y budesonide
EA201370162A1 (ru) Новая фармацевтическая композиция со слабым побочным эффектом, включающая противотуберкулезные препараты
MX2015012315A (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
BR112015012497A2 (pt) combinações farmacêuticas
UY35890A (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
AR102903A1 (es) Inhalador de polvo seco
TW201613600A (en) Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically
BR112018072183A2 (pt) composição farmacêutica, e, método para prevenir uma doença de pele
MX385725B (es) Composición farmacéutica que comprende sumatriptán para tratamiento de migraña.
TH173838A (th) เครื่องพ่นละอองยาผงแห้ง
AR098868A1 (es) Composición farmacéutica en polvo seco para inhalación
AR114012A1 (es) Método para proporcionar terapia de celiprolol a un paciente
UA96221U (uk) Спосіб лікування хворих на туберкульоз органів дихання